Active Clinical Trials and Research Studies on EGIDs

Please click on the link to learn more details about the trial, its purpose, who may participate, locations, and phone numbers. Please seek advice from your medical teams about the clinical trials or studies you are interested in. The items are listed in date order & updated periodically:

ENGAGE – adults and adolescents who have EoG with or without EoD

Is eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD) affecting your daily life?

The below website link provides information about a clinical study, Engage, for adults and adolescents who have EoG with or without EoD. Currently, there is no suitable long-term treatment for EoG. Considering this gap in treatment, the Engage clinical research study aims to assess the safety and efficacy of a study drug in treating EoG in adults and adolescents.

Click to learn more about the study

PilOt Assessment To Find Evidence Of Gastric Motility Abnormalities In Eosinophilic Gastric Disorders" (OAT-FEED)

The trial is being conducted to learn whether there are problems with stomach emptying in patients with Eosinophilic gastritis. Participation may last up to 20 weeks.

Click to learn more about participating in the study

EOE Trial & You

The CROSSING study for adults and adolescents with EoE

The CROSSING clinical research study is evaluating the safety and efficacy of tezepelumab for the treatment of Eosinophilic Esophagitis (EoE) in patients between 12 and 80 years of age.

Click to learn more about participating in the study or call 844-432-3890

Flute 3 -Advancing Oral Treatment Options for People with Eosinophillic Esophagitis (EoE)

If you have difficulty swallowing or if food going down feels uncomfortable, you may have EoE. If you are diagnosed with EoE, you may be able to participate in a clinical trial called FLUTE 3 (FLUTicasone propionate in Eosinophilic esophagitis) assessing APT-1011. APT-1011 is an investigational tablet that is placed on the back of the tongue once a day at bedtime. After the tablet melts (in less than 30 seconds) it is swallowed to coat the esophagus. The clinical trial FLUTE 3, will evaluate if APT-1011 treats the inflammation causing your EoE symptoms.

To learn more visit Ellodi Pharmaceuticals

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC- 93538 in adult and adolescent participants with eosinophilic esophagitis (EoE). The study will incorporate a 24-week Induction Phase followed by a 24-week Maintenance Phase. Participants will be randomized at the beginning of the study into 3 treatment arms: – Placebo for Induction and Maintenance – CC-93538 360 mg Subcutaneous (SC) once weekly for Induction followed by 360 mg SC once every other week for Maintenance – CC-93538 360 mg SC once weekly for Induction and Maintenance

To check eligibility answer these few questions.

To learn more visit, Bristol Myers Squibb

DESTINY study for adults with HES Expand

To check eligibility take this survey

Informational Brochure

Fact Sheet

This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy.

The study will recruit patients with a confirmed diagnosis of HES and who are on stable HES therapy for at least 4 weeks prior to randomization (Visit 2). Eligible participants must have uncontrolled HES with a history of repeated flare (≥2 flares in the previous 12 months) and blood eosinophil count of ≥1,000 cells/ microliter (μL) during Screening. Historical HES flares are defined as documented HES-related worsening of clinical symptoms or blood eosinophil counts requiring an escalation in therapy.

Participants who meet the inclusion and exclusion criteria will be randomized in a 2:1 ratio to receive either depemokimab or placebo while continuing their SoC HES therapy.

To learn more visit Glaxo Smith Kline

OCEAN study for adults with EGPA

A GSK clinical trial: This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.

Informational Brochure

Study Fact Sheet


To learn more visit Ocean Clinical Trial

Study in Pediatrics with HypEREosinophilic syndrome (SPHERE)

Informational Brochure  

Study Fact Sheet

A GSK clinical trial: The purpose of this study is to investigate the efficacy and safety of mepolizumab in children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard-of-care (SoC) therapy.

To learn more visit GSK

Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab (MANDARA)

How to participate: NCT04157348


Study Start Date: November 2019

Contact: Clinic Location based on Location

To learn more visit

A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES) (NATRON)

How to participate: NCT04191304

Study Website: NATRON


Study Start Date: December 2019

Contact: visit Study Website

Benralizumab Eosinphilic Gastritis Study 

For children, teens, and adults 12 to 60 years old

How to participate: Benralizumab Eosinphilic Gastritis Study brochure_Final

Cincinnati Children’s Hospital Medical Center

Contact: Marc Rothenberg, MD, PhD
(513) 803-0257

Cristin Murray-Petzold
(513) 803-9079

OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages

Study Start Date: June 2015

National Institute of Allergy and Infectious Diseases (NIAID)

How to Participate: NTC02523118

To learn more visit

Esophageal String Test in Eosinophilic Esophagitis

Study Start Date: December 2013

University of Colorado, Denver

How to Participate: NTC02008903

To learn more visit

Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders

Study Start Date: December 2005

Children’s Hospital Medical Center, Cincinnati

How to Participate: NTC00267501

To learn more visit

Completed Clinical Trials


Food Antigen in Eosinophilic Esophagitis (EoE)

Read more

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis (EoDyssey)

Read more

A Study of Benralizumab in Patients With Eosinophilic Esophagitis (MESSINA) (terminated)

Read more


Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

Read more


Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) (FLUTE)

Read more


Budesonide Effervescent Tablet vs. Placebo in Active Eosinophilic Esophagitis (EOS-1)

Read more


Dysregulation of the Wnt pathway in adult eosinophilic esophagitis

Read more

Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

Read more


Trial of Montelukast in Eosinophilic Esophagitis

Read more

Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis

Read more

Meritage commences OBS Phase 2 clinical trial for eosinophilic esophagitis

Read more

Data Bank for Eosinophilic Disorders

Read more

A Study of Flovent in Patients With Eosinophilic Esophagitis

Read more


The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis

Read more

Topical Steroid Treatment for Eosinophilic Esophagitis

Read more

Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis

Read more


Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis

Read more

Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years

Read more

Eosinophilic Esophagitis: Influence of Dilation on Dysphagia and Inflammation

Read more


Omalizumab to Treat Eosinophilic Gastroenteritis

Read more